Immunotherapy for Guillain-Barré syndrome

Lancet Neurology

Volumn 3, Issue 2, 2004, Pages 84-

  Van Doorn, Pieter A ^a   Van Koningsveld, Rinske ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; METHYLPREDNISOLONE; STEROID;

CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOTHERAPY; META ANALYSIS; PALLIATIVE THERAPY; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SHORT SURVEY; TREATMENT OUTCOME;

EID: 1642473139     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(03)00660-4     Document Type: Letter

References (6)

1. Hahn A.F. Guillain-Barré syndrome. Lancet. 352:1998;635-641.
2. Hughes R.A.C., Wijdicks E.F.M., Barohn R., et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 61:2003;736-740.
3. Raphaël JC, Chevret S, Hughes RAC, Annane D. @ Plasma exchange for Guillain-Barré syndrome (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software.
4. Hughes RAC, Raphaël JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software.
5. Hughes RAC, van der Meché FGA. Corticosteroids for Guillain-Barré syndrome (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software.
6. Van Koningsveld R., Schmitz P.I.M., van der Meché G.F.A., et al. Randomised trial on the additional effect of methylprednisolone on standard treatment with intravenous immunoglobulin in Guillain-Barré syndrome. Lancet. 363:2004;192-196.